Results 11 to 20 of about 108,133 (341)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2016
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade.
Yu Mi Kang, Chang Hee Jung
doaj   +3 more sources

Glucagon-like peptide-1 receptor agonists in neoplastic diseases

Frontiers in Endocrinology
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids.
Lisan Ji, Xianzhen He, Xinwen Min, Handong Yang, Wenwen Wu, Hao Xu, Jun Chen, Jun Chen, Aihua Mei   +8 more
doaj   +3 more sources

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +3 more sources

Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists

JAMA Health Forum
This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists.
Ashwin K. Chetty, Mahima Chillakanti, Reshma Ramachandran, Joseph S Ross, Alissa S. Chen   +4 more
semanticscholar   +3 more sources

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +2 more sources

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study

Obesity Surgery, 2023
Purpose Weight regain after bariatric surgery occurs in up to a third of patients and reduces treatment-associated health benefits. The efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) for treatment of type 2 diabetes mellitus and obesity ...
Anders Boisen Jensen, F. Renström, S. Aczél, P. Folie, M. Biraima-Steinemann, Felix Beuschlein, S. Bilz   +6 more
semanticscholar   +1 more source

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

BMJ Open Diabetes Research & Care, 2022
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes mellitus (T2DM) treatment with demonstrated weight loss benefits in clinical trials.
Tracey Weiss, Lingfeng Yang, R. Carr, Sampriti Pal, B. Sawhney, R. Boggs, S. Rajpathak, K. Iglay   +7 more
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Metabolites, 2021
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs).
A. Mantovani, Graziana Petracca, Giorgia Beatrice, A. Csermely, A. Lonardo, G. Targher   +5 more
semanticscholar   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
doaj   +2 more sources

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +5 more sources